Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide Dose Finding for Weight Management
NCT03856047Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2019
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of cagrilintide in obesity, Overweight, sponsored by Novo Nordisk. Started Mar 2019; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03856047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856047.